Drug Profile
Research programme: neurokinin-3 receptor modulators - Ogeda
Alternative Names: ESN-314Latest Information Update: 18 May 2017
Price :
$50
*
At a glance
- Originator Euroscreen
- Developer Ogeda
- Class Small molecules
- Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists; Neurokinin 3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Endometriosis; Polycystic ovary syndrome
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in Belgium (PO)